% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gilbert:300347,
      author       = {J. A. Gilbert and M. B. Azad and F. Bäckhed and M. J.
                      Blaser and M. Byndloss and C. Y. Chiu and H. Chu and L. R.
                      Dugas and E. Elinav$^*$ and S. M. Gibbons and K. E. Gilbert
                      and M. R. Henn and S. L. Ishaq and R. E. Ley and S. V. Lynch
                      and E. Segal and T. D. Spector and P. Strandwitz and J. Suez
                      and C. Tropini and K. Whiteson and R. Knight},
      title        = {{C}linical translation of microbiome research.},
      journal      = {Nature medicine},
      volume       = {31},
      number       = {4},
      issn         = {1078-8956},
      address      = {[New York, NY]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-00781},
      pages        = {1099-1113},
      year         = {2025},
      note         = {2025 Apr;31(4):1099-1113},
      abstract     = {The landscape of clinical microbiome research has
                      dramatically evolved over the past decade. By leveraging in
                      vivo and in vitro experimentation, multiomic approaches and
                      computational biology, we have uncovered mechanisms of
                      action and microbial metrics of association and identified
                      effective ways to modify the microbiome in many diseases and
                      treatment modalities. This Review explores recent advances
                      in the clinical application of microbiome research over the
                      past 5 years, while acknowledging existing barriers and
                      highlighting opportunities. We focus on the translation of
                      microbiome research into clinical practice, spearheaded by
                      Food and Drug Administration (FDA)-approved microbiome
                      therapies for recurrent Clostridioides difficile infections
                      and the emerging fields of microbiome-based diagnostics and
                      therapeutics. We highlight key examples of studies
                      demonstrating how microbiome mechanisms, metrics and
                      modifiers can advance clinical practice. We also discuss
                      forward-looking perspectives on key challenges and
                      opportunities toward integrating microbiome data into
                      routine clinical practice, precision medicine and
                      personalized healthcare and nutrition.},
      subtyp        = {Review Article},
      cin          = {D480},
      ddc          = {610},
      cid          = {I:(DE-He78)D480-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40217076},
      doi          = {10.1038/s41591-025-03615-9},
      url          = {https://inrepo02.dkfz.de/record/300347},
}